Clinical Trial Detail

NCT ID NCT04088188
Title Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Academic and Community Cancer Research United
Indications

cholangiocarcinoma

Therapies

Cisplatin + Gemcitabine + Pemigatinib

Cisplatin + Gemcitabine + Ivosidenib

Age Groups: senior adult

Additional content available in CKB BOOST